ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

GWPH GW Pharmaceuticals PLC

218.96
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Name Symbol Market Type
GW Pharmaceuticals PLC NASDAQ:GWPH NASDAQ Depository Receipt
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  0.00 0.00% 218.96 218.95 219.69 0 01:00:00

Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or ...

05/05/2021 1:54pm

Edgar (US Regulatory)


NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-35892
Issuer: GW PHARMACEUTICALS PLC
Exchange: Nasdaq Stock Market LLC
(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
Address: Sovereign House, Vision Park
Histon,
UNITED KINGDOM
SP4 0JQ UK
Telephone number: (44) 1223 266 800
(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
American Depositary Shares
(Description of class of securities)
Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
o 17 CFR 240.12d2-2(a)(1)
o 17 CFR 240.12d2-2(a)(2)
x 17 CFR 240.12d2-2(a)(3)
o 17 CFR 240.12d2-2(a)(4)
o  Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
o  Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
Pursuant to the requirements for the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
2021-05-05ByO'Neil BlakeSenior Specialist
Date NameTitle
1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

1 Year GW Pharmaceuticals Chart

1 Year GW Pharmaceuticals Chart

1 Month GW Pharmaceuticals Chart

1 Month GW Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock